Revenue - Narrative (Details) - USD ($)			12 Months Ended		47 Months Ended	48 Months Ended
	Dec. 11, 2020	Sep. 19, 2018	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2022	Sep. 30, 2022	Apr. 17, 2018
Disaggregation of Revenue [Line Items]
Royalty revenue			$ 40,725,185	$ 27,401,919
Grants receivable							$ 7,400,000
Deferred revenue, period increase (decrease)			3,000,000	1,000,000
Grant
Disaggregation of Revenue [Line Items]
Royalty revenue			3,300,000	1,600,000
Research And Development Arrangement September 19, 2018
Disaggregation of Revenue [Line Items]
Royalty revenue			$ 3,700,000	$ 700,000
Scenario, Forecast | Grant
Disaggregation of Revenue [Line Items]
Royalty revenue					$ 7,400,000
Biomedical Advanced Research and Development Authority (BARDA)
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement	$ 3,500,000	$ 4,600,000
Biomedical Advanced Research and Development Authority (BARDA) | Plan
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement		$ 8,100,000
Biomedical Advanced Research and Development Authority (BARDA) | Scenario, Forecast
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement						$ 6,500,000